AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02982616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dodecanoic acid
Description: The middle chain saturated fatty acid that can be widely found in daily food.
Study NCT02982616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive emotion
Description: Positive emotion induced by facial expressions and classic music.
Study NCT02982616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline
Study NCT02982616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: saline
Description: saline
Study NCT02982616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neutral emotion
Description: Neutral emotion induced by facial expressions and classic music.
Study NCT02982616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: neutral emotion
Description: Neutral emotion induced by facial expressions and classic music.
Study NCT02651415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is \<30% fat, \~300-550 calories.
Study NCT02651415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEIT
Description: For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEIT
Description: For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOCE
Description: For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOCE
Description: For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOCE plus PEIT
Description: A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOCE plus PEIT
Description: A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOCE plus RFA
Description: For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
Study NCT01018381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOCE plus RFA
Description: For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
Study NCT01018381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MGN-3
Description: For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
Study NCT01018381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
Study NCT01018381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
Study NCT03551951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test for circulating tumor cells, DNA alterations
Study NCT01980901 — intervention group
Intervention type: DEVICE
Intervention: Ovation™/Ovation Prime™ Abdominal Stent Graft System
Description: Single occurence permanent implant of AAA device.
Study NCT01235975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK 134612
Description: Intramuscular injection
Study NCT01235975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MencevaxACWY TM
Description: Subcutaneous injection
Study NCT00791921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
Study NCT00791921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CDP870
Description: Placebo given every 2 weeks until Week22 (SC)
Study NCT06619470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: binaural beats
Description: binaural beats
Study NCT06619470 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: binaural beats
Description: binaural beats
Study NCT04825821 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical and ultrasonographic assessment
Description: Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures
Study NCT00558896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
Study NCT00558896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
Study NCT00705458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography
Description: 64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
Study NCT00705458 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Nuclear Myocardial Perfusion Imaging
Description: Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
Study NCT00996411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvinorin A
Description: This is an initial dose ranging study
Study NCT01367496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Description: Dose 1
Study NCT01367496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Description: Dose 2
Study NCT01367496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Description: Dose 3
Study NCT01367496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone (MNTX)
Study NCT02381938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles
Description: 6-month intervention to increase physical activity and improve other health related behaviors
Study NCT02381938 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Finances
Description: 6-month intervention to educate and improve financial health
Study NCT03611231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study NCT01877356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral spinal anesthesia
Description: prilocaine plain 2% 50 mg
Study NCT01877356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral spinal anesthesia
Description: prilocaine 2% hyperbaric 30 mg
Study NCT01323153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: Oral doses of 600 mg once daily for 20 weeks
Study NCT01323153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
Study NCT00497978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: taurine
Description: 6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
Study NCT00497978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
Study NCT04721704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin+ Amoxicillin + Omeprazole
Description: In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
Study NCT04721704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole +Amoxicillin + Omeprazole
Description: Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
Study NCT01500408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a (current approved manufacturing process invloving FBS)
Description: Single dose of 60 mcg given Intramuscularly (IM)
Study NCT01500408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a (new process, manufactured without FBS)
Description: Single dose of 60 mcg given Intramuscularly (IM)
Study NCT03219151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eMAR game
Description: The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
Study NCT03219151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal pre-work
Description: Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
Study NCT03219151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal pre-work
Description: Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based sessions (28 total) on a structured schedule
Description: 28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone-based sessions upon request
Description: For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight self-monitoring
Description: Each randomized participant will be given a Body Trace scale that will electronically record their weight.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight self-monitoring
Description: Each randomized participant will be given a Body Trace scale that will electronically record their weight.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity self-monitoring
Description: Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and physical activity self-monitoring
Description: Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled tailored interventionist feedback
Description: Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary goals
Description: Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary goals
Description: Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal replacements
Description: Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity goals
Description: Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity goals
Description: Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolbox
Description: The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenges
Description: There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
Study NCT02063178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored interventionist feedback upon request
Description: Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
Study NCT02560324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Study NCT02560324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01446276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500 mg 3 times daily for six month
Study NCT01446276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet 3 times daily for six month
Study NCT02134002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Study NCT02134002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Study NCT02143791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst and Tonic stimulation
Study NCT03375879 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage contact lens
Description: Bandage contact lens
Study NCT01237249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Study NCT01237249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT01237249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Study NCT01237249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Study NCT01237249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02550600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iLA activve treatment
Description: iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow).
Study NCT02550600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group.
Study NCT04605380 — intervention group
Intervention type: OTHER
Intervention: Virtual reality online world
Description: Virtual patient with open fracture inside a virtual world
Study NCT02678585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: 53 patients received intravenous regional lidocaine plus nalbuphine
Study NCT02678585 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: 53 patients received intravenous regional lidocaine
Study NCT03336268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POINT
Description: A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
Study NCT02657577 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study NCT03184337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC's PreventT2 Program
Description: The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.